HIV/AIDS is one of the diseases and crosscutting challenge that has affected millions of people across the globe. In trying to fight the epidemic, different organisations have partnered to find a last solution that has include preventive vaccines, and prevention of transmission of the virus to non negative population among others.
In partnership with the United States of America Division of AIDS (DAIDS), the Centre for Infectious Disease Research in Zambia (CIDRZ) has been involved in research aimed at providing an effective vaccine and develop prevention strategies of HIV/AIDS.
In giving an overview of the Division of AIDS, Ms. Teri Greenfield, Program Officer in the Office of Clinical Site Oversight (OCSO), Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Diseases (NIAID) explained the role of the DAIDS in the fight to end HIV/AIDS.
“Division of AIDS develops and supports the infrastructure and biomedical research needed to halt the spread of HIV through the development of an effective vaccine and biomedical prevention strategies that are safe and desirable. we also develop the novel approaches for the treatment and cure of HIV infection, and we treat or prevent HIV co-infections and co-morbidities of greatest significance, ” Ms. Greenfield said.
Division of AIDS has over the years partnered with scientific and community stakeholders to efficiently implement effective interventions. It facilitates the clinical research of the scientific programs through oversight of clinical site capabilities and overall performance.
Ms. Greenfield further explained that the organisation provides expertise on all pharmaceutical aspects of protocol development and conduct.
“The organisation coordinates and oversees the management of study products for DAIDS-supported clinical trials and it provides oversight and monitor adherence to quality assurance standards and standard operating procedures for all pharmacy and product-related issues at sites.” She added.
Division of AIDS also manages clinical site monitoring contract to ensure research is conducted at sites according to International Conference on Harmonisation (ICH) E6(R2) – Good Clinical Practice (GCP) as well as DAIDS policies and local regulations.